Compare OMEX & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMEX | SCLX |
|---|---|---|
| Founded | 1986 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.9M | 55.1M |
| IPO Year | 2024 | 2020 |
| Metric | OMEX | SCLX |
|---|---|---|
| Price | $0.85 | $6.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 354.7K | 65.4K |
| Earning Date | 05-11-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $9,327.00 | ★ $30,253,000.00 |
| Revenue This Year | N/A | $122.52 |
| Revenue Next Year | N/A | $186.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $4.20 |
| 52 Week High | $4.43 | $34.27 |
| Indicator | OMEX | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 38.14 |
| Support Level | $0.74 | $6.23 |
| Resistance Level | $0.97 | $7.77 |
| Average True Range (ATR) | 0.07 | 0.41 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 72.74 | 32.64 |
Odyssey Marine Exploration Inc is a deep-ocean exploration company. It discovers, validates, and develops high-value seafloor mineral resources and provides specialized mineral exploration, project development, and marine services to its clients. The company's subsea project portfolio contains multiple projects in various stages of development, such as the Phosagmex Project, a rich deposit of phosphate sands located seventy-ninety meters deep within the Mexican EEZ; two polymetallic nodule exploration license holders in the Cook Islands' EEZ; the Lihir Gold Project, a subsea area that contains several prospective gold exploration targets located in the Papua New Guinea Exclusive Economic Zone (EEZ); and others.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.